Teva's stock has tumbled over 8 sessions and Morgan Stanley says it could fall 16% more - MarketWatch
Teva shares surge on corporate shake-up - MarketWatch
Latest twist in pharma love triangle as Teva pursues Mylan merger - MarketWatch
Teva releases generic version of Mylan's EpiPen in limited doses in the U.S. - MarketWatch
Teva Pharmaceutical Shares Real-World Data Of ProAir Digihaler In Asthma Patients
There's scant evidence so far for chloroquine as a COVID-19 drug — but there's already a shortage - MarketWatch
Teva Poised to Get a Big Boost in Generics - WSJ
Israel stocks ease; Teva loses patent ruling - MarketWatch
Israel stocks up; FTC eyes Teva-Cephalon deal - MarketWatch
Teva beats first-quarter expectations but still has the same old problems - MarketWatch
Teva Pharmaceutical TEVA Pivots Trading Plans and Risk Controls - MarketWatch
Teva earnings preview: Opioid suits are 'key' - MarketWatch
Teva Pharmaceutical TEVA Pivots Trading Plans and Risk Controls - MarketWatch
Teva stock drops on guidance, manufacturing problems - MarketWatch
Teva Pharmaceutical Settles Opioid Suit With West Virginia - MarketWatch
Israel stocks lower; Ness agrees to takeover - MarketWatch
Mylan tries to fend off Teva with bigger bid for Perrigo - MarketWatch
Is the new Teva x Ugg collection fashion-forward or just plain ugly? - MarketWatch
Billionaire health-care investor Phillip Frost charged by SEC with pump-and-dump schemes - MarketWatch
Teva's generic EpiPen approved in the U.S., with perfect timing - MarketWatch
Teva beats first-quarter expectations but still has the same old problems - MarketWatch
Drug stocks move higher in late trading - MarketWatch
Is the new Teva x Ugg collection fashion-forward or just plain ugly? - MarketWatch
Teva Pharmaceutical to pay $110 mln to settle opioid charges in W. Va. - MarketWatch
What To Do After TEVA Stock Falls Below $10 Again (NYSE:TEVA) | Seeking Alpha
Tel Aviv losing streak extends into third day - MarketWatch
Teva's stock has tumbled over 8 sessions and Morgan Stanley says it could fall 16% more - MarketWatch
